UNICREDIT BANK/CALL/ROCHE GS/235/0.1/18.09.24 Stock

Warrant

DE000HD62GY1

Real-time BOERSE MUENCHEN 09:47:01 2024-07-05 EDT
1.52 EUR +6.29% Intraday chart for UNICREDIT BANK/CALL/ROCHE GS/235/0.1/18.09.24
Current month-26.67%
1 month+44.44%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 1.52 +6.29%
24-07-04 1.43 -11.73%
24-07-03 1.62 -13.37%
24-07-02 1.87 -4.10%
24-07-01 1.95 0.00%

Real-time BOERSE MUENCHEN

Last update July 05, 2024 at 09:47 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer UniCredit UniCredit
WKN HD62GY
ISINDE000HD62GY1
Date issued 2024-06-03
Strike 235 CHF
Maturity 2024-09-18 (75 Days)
Parity 10 : 1
Emission price 0.96
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.41
Lowest since issue 0.84
Delta0.68x
Omega 11.96
Premium2.18x
Gearing17.51x
Moneyness 1.037
Difference Strike -8.85 CHF
Difference Strike %-3.77%
Spread 0.02
Spread %1.39%
Theoretical value 1.450
Implied Volatility 20.50 %
Total Loss Probability 35.90 %
Intrinsic value 0.8638
Present value 0.5862
Break even 249.10 €
Theta-0.04x
Vega0.04x
Rho0.03x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
243.4 CHF
Average target price
276.4 CHF
Spread / Average Target
+13.57%
Consensus